[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649294":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":48,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Semmelweis University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Chronic ocular allergic inflammation",null,"Topical 1% cyclosporin applied for treatment Chronic ocular allergic inflammation",[13],"Drug: Topical Cyclosporine 1%",{"label":15,"type":10,"description":16,"interventionNames":17},"Blepharokeratoconjunctivitis","Blepharokeratoconjunctivitis patients who have accompaining blepharitis and ocular surface inflammation as well",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Topical Cyclosporine 1%","Dosage may differ from severe dry eye indication",[15,9],[25],{"name":26,"affiliation":5,"role":27},"Amarilla Barcsay-Veres, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Lim Lu Hyoun","CONTACT","+3614591500","luhyoun21c@gmail.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":10,"geoPoint":10,"contacts":43},"Semmelweis University Department of Ophthalmology","RECRUITING","Budapest","Pest County","1085","Hungary","HU",[44],{"name":45,"role":31,"phone":46,"phoneExt":10,"email":47},"Amarilla Barcsay-Veres, MD.PhD.","003614591500","veres.amarilla@semmelweis.hu",{"type":27,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Luhyoun Lim","Medical Doctor","100649294","treatment-of-ocular-surface-inflammations-100649294",false,"NCT07732855","Treatment of Ocular Surface Inflammations","Treatment of Ocular Surface Inflammations With 1% Cyclosporine (Ikervis) Eye Drops","Inclusion Criteria:\n\n* ocular surface inflammatory disease cornea inflammation -keratitis\n\nExclusion Criteria:\n\n* eye surgery within 1 year, lack of fitness for the objective ocular surface measurments","ALL","4 Years","60 Years",{"count":62,"type":63},50,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to learn if topical Cyclosporine 1% works to treat severe allergic ocular surface inflammation in pediatric population. The study will evaluate the efficacy and safety of topical Cyclosporine 1%.\n\nThe main questions it aims to answer are:\n\nDoes topical Cyclosporine 1% lower the number of times participants need to use a rescue steroid? What medical problems do participants have when taking topical Cyclosporine 1%?\n\nParticipants will:\n\nTake topical Cyclosporine 1% every day for months. Visit the clinic once every 2-6 weeks for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication. spelling errors\u002Ftypos and update as appropriate.",[67,68,69],"Ocular Surface Allergy","Conjunctivitis, Allergic","Blepharoconjunctivitis","2026-07-31",{"date":72,"type":73},"2026-08-03","ACTUAL",{"date":75,"type":73},"2025-06-10",{"date":77,"type":63},"2028-12",{"name":5,"class":6},1]